Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quinapril + losartan is a combination of two antihypertensive agents, each with a distinct mechanism of action. Quinapril is an angiotensin-converting enzyme (ACE) inhibitor that works by blocking the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure[1][7]. Losartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to its receptors on blood vessels, also resulting in vasodilation and lower blood pressure[3][6]. The combination aims for more comprehensive inhibition of the renin-angiotensin system than either agent alone. This dual blockade may provide enhanced suppression of cardiac sympathetic activity and greater antihypertensive effects compared to monotherapy[5]. Both drugs are primarily indicated for the treatment of hypertension; quinapril may also be used in heart failure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quinapril + losartan.